NO331207B1 - Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav - Google Patents

Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav

Info

Publication number
NO331207B1
NO331207B1 NO20004502A NO20004502A NO331207B1 NO 331207 B1 NO331207 B1 NO 331207B1 NO 20004502 A NO20004502 A NO 20004502A NO 20004502 A NO20004502 A NO 20004502A NO 331207 B1 NO331207 B1 NO 331207B1
Authority
NO
Norway
Prior art keywords
eprosartan
preparation
pharmaceutical composition
composition
solvate
Prior art date
Application number
NO20004502A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004502L (no
NO20004502D0 (no
Inventor
Gopadi M Venkatesh
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20004502D0 publication Critical patent/NO20004502D0/no
Publication of NO20004502L publication Critical patent/NO20004502L/no
Publication of NO331207B1 publication Critical patent/NO331207B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
NO20004502A 1998-03-11 2000-09-08 Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav NO331207B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7766098P 1998-03-11 1998-03-11
PCT/US1999/004651 WO1999045779A1 (en) 1998-03-11 1999-03-11 Novel compositions of eprosartan

Publications (3)

Publication Number Publication Date
NO20004502D0 NO20004502D0 (no) 2000-09-08
NO20004502L NO20004502L (no) 2000-11-07
NO331207B1 true NO331207B1 (no) 2011-10-31

Family

ID=22139347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004502A NO331207B1 (no) 1998-03-11 2000-09-08 Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav

Country Status (21)

Country Link
EP (1) EP1061803B1 (cs)
JP (1) JP2002506010A (cs)
KR (1) KR20010041796A (cs)
CN (1) CN1299235A (cs)
AT (1) ATE508633T1 (cs)
AU (1) AU757547B2 (cs)
BR (1) BR9908691A (cs)
CA (1) CA2323363C (cs)
CY (1) CY1111738T1 (cs)
CZ (1) CZ303067B6 (cs)
DK (1) DK1061803T3 (cs)
ES (1) ES2366394T3 (cs)
HU (1) HU228574B1 (cs)
IL (1) IL138345A (cs)
NO (1) NO331207B1 (cs)
NZ (1) NZ506700A (cs)
PL (1) PL192545B1 (cs)
SI (1) SI1061803T1 (cs)
TR (1) TR200002646T2 (cs)
WO (1) WO1999045779A1 (cs)
ZA (1) ZA991922B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4990696A (en) 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
TR200100172T2 (tr) * 1998-07-20 2001-05-21 Smithkline Beecham Corporation Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
PE20020082A1 (es) * 2000-04-12 2002-02-21 Novartis Ag Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004064834A1 (en) * 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
JP3874419B2 (ja) 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
WO2006000564A1 (en) * 2004-06-23 2006-01-05 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
WO2009013760A2 (en) * 2007-07-25 2009-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate
CN103705510A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种阿齐沙坦固体组合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS587609B2 (ja) 1979-06-17 1983-02-10 フロイント産業株式会社 粉体薬剤のコ−テング法
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
UA49880C2 (uk) * 1996-03-29 2002-10-15 Смітклайн Бічам Корпорейшн Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі
ATE341325T1 (de) * 1997-08-06 2006-10-15 Smithkline Beecham Corp Eprosartan arginyl-ladungsneutralisationskomplex und verfahren zu dessen herstellung und verabreichung

Also Published As

Publication number Publication date
CA2323363C (en) 2008-09-30
KR20010041796A (ko) 2001-05-25
IL138345A0 (en) 2001-10-31
PL192545B1 (pl) 2006-11-30
HUP0101243A1 (hu) 2002-05-29
ATE508633T1 (de) 2011-05-15
DK1061803T3 (da) 2011-08-29
ES2366394T3 (es) 2011-10-19
JP2002506010A (ja) 2002-02-26
CZ303067B6 (cs) 2012-03-21
CA2323363A1 (en) 1999-09-16
PL343411A1 (en) 2001-08-13
CN1299235A (zh) 2001-06-13
NO20004502L (no) 2000-11-07
AU2890999A (en) 1999-09-27
TR200002646T2 (tr) 2001-01-22
NZ506700A (en) 2003-03-28
NO20004502D0 (no) 2000-09-08
HU228574B1 (en) 2013-04-29
EP1061803A4 (en) 2007-12-26
BR9908691A (pt) 2000-12-26
AU757547B2 (en) 2003-02-27
CY1111738T1 (el) 2015-10-07
IL138345A (en) 2004-12-15
EP1061803A1 (en) 2000-12-27
ZA991922B (en) 1999-09-13
EP1061803B1 (en) 2011-05-11
CZ20003288A3 (cs) 2001-03-14
WO1999045779A1 (en) 1999-09-16
SI1061803T1 (sl) 2011-09-30
HUP0101243A3 (en) 2005-09-28

Similar Documents

Publication Publication Date Title
CY1111738T1 (el) Συνθeσεις επροσαρτανης
WO2000004862A3 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
MY127793A (en) Novel form of s-omeprazole.
EP1504776A4 (en) ELEMENT FOR REGENERATING THE ARTICULATED ORANGE AND METHOD FOR THE PRODUCTION THEREOF, METHOD FOR REGENERATING ARTICLES OF ARTICLES AND ARTIFICIAL CARTILES FOR A TRANSPLANTATION
DE60034728D1 (de) Verfahren zur Massenanfertigung von beschichteten, elektrochirurgischen Elektroden
RO118870B1 (ro) Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice
TR199800608A3 (tr) Propanolamin türevleri, bunlarin üretim usulü.
NO20043371L (no) Kortikotropinfrigjorendefaktorreseptor-2 agonister
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE50012584D1 (de) Keramikhaltiges dispergat, verfahren zu dessen herstellung und verwendung des dispergates in dickschichtpasten
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
WO2006052461A3 (en) Novel formulations of eprosartan with enhanced bioavailability
DE60129933D1 (de) Verfahren zum screening
MY118704A (en) Process for preparation of eprosartan
ZA200005540B (en) New hydroxyindoles, their use as phosphodiestrase 4 inhibitors and method for producing same.
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах
DE69615276D1 (de) Verbessertes Verfahren zur Herstellung von 5-(Alkoxymethyl)-pyridin-2,3-dicarboxylat Salz
WO2000073333A3 (en) Ligand for cd7, and methods for use thereof
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
YU58702A (sh) Postupak za proizvodnju 5-arilnikotinaldehida
FR2842516B1 (fr) Composition d'ensimage pour verranne, procede utilisant cette composition et produits resultants
DE60130385D1 (de) Verfahren zur Erhöhung der Eierproduktion und Verfestigung von Eierschalen bei Geflügel
DE50010843D1 (de) Carboxamid-substituierte benzimidazol-derivate, verfahren zu ihrer herstellung und ihre verwendung als tryptase-inhibitoren
WO2000041472A3 (de) Bindungspartner für 5-ht5-rezeptoren zur migränebehandlung
FR2854890B1 (fr) Procede de formation d'une liaison carbone-heteroatome

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees